Table 1.
Comparison of disease presentation and molecular findings between prairie dog treatment groupsa
| ST-246 treatment |
Symptoms (no. of PDs affected) | Day of symptom onset | Day of rash onset | Lesion count | No. of surviving PDs | Day(s) of MPXV DNA detection in: |
Days of viable virus detection | Detection of Ig antibody (no. of positive PDs) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Group (n)b | Day(s) of administration | Swabs | Blood | |||||||
| Prophylaxis (4) | 0–13 | NA | NA | NA | NA | 4 | 8–26 | 24 (PD10) | 12–24 | 4 |
| Postexposure (4) | 3–16 | NA | NA | NA | NA | 4 | 6–28 | None | 8–26 | 4 |
| Therapeutic (4) | 10–23, 24–37 (PD3) | Facial swelling, nasal discharge, nasal crust, bloody nose, inappetance, weight loss, pustular lesions (4) | 8 (PD2, PD12, PD14), 24 (PD3) | 10 (PD2, PD12, PD14), 24 (PD3) | <10 (PD2, PD12, PD14), >50 (PD3) | 4 | 4–30 | 6–26 (PD2, PD3, PD14) | 4–30 | 3 (PD2, PD3, PD14) |
| Vehicle control (4) | None | Facial swelling, nasal discharge, nasal crust, bloody nose, inappetance, weight loss, pustular lesions, petechial rash, mouth breathing (3) | 8 (PD5, PD8, PD15) | 10 (PD8) | 10–25 (PD8) | 1 (PD6) | 4–12 (PD5, PD8, PD15) | 4–12 (PD5, PD8, PD15) | 6–12 (PD5, PD8, PD15) | 1 (PD8) |
| Uninfected control (2) | 3–16 | NA | NA | NA | NA | 2 | None | None | None | 0 |
a
Clinical and molecular observations in prairie dogs (PDs) infected with MPXV and treated with ST-246. Prairie dogs were inoculated intranasally with 3.8 × 105 PFU of MPXV or mock infected with PBS and treated orally with ST-246 or vehicle for a period of 14 days. Observations were recorded for 30 days p.i., with swab and blood sample collections every 2 days for analysis of viral DNA and viable virus. Serum was collected from blood and monitored for antibody production. Specific PDs are indicated in parentheses where appropriate.
b
Therapeutic, post-rash onset; n, number of animals.